Ascendis Pharma A/S (ASND)
Automate Your Wheel Strategy on ASND
With Tiblio's Option Bot, you can configure your own wheel strategy including ASND - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ASND
- Rev/Share 6.1431
- Book/Share -3.1625
- PB -48.6822
- Debt/Equity -4.4639
- CurrentRatio 1.0406
- ROIC -0.5064
- MktCap 9294868331.7057
- FreeCF/Share -5.1255
- PFCF -30.215
- PE -27.044
- Debt/Assets 0.7982
- DivYield 0
- ROE 1.9142
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ASND | Morgan Stanley | Equal Weight | Overweight | -- | $250 | May 5, 2025 |
| Initiation | ASND | RBC Capital Mkts | -- | Outperform | -- | $205 | April 16, 2025 |
| Initiation | ASND | UBS | -- | Buy | -- | $196 | Jan. 7, 2025 |
| Upgrade | ASND | Oppenheimer | Perform | Outperform | -- | $180 | Sept. 5, 2024 |
News
FDA Accepts TransCon® CNP NDA for Priority Review
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo
Read More
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Read More
Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Read More
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
Read More
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Published: February 13, 2025 by: Benzinga
Sentiment: Positive
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Read More
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel …
Read More
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
Read More
About Ascendis Pharma A/S (ASND)
- IPO Date 2015-01-28
- Website https://ascendispharma.com
- Industry Biotechnology
- CEO Mr. Jan Moller Mikkelsen
- Employees 1017